Clearly further analysis is needed on the data before drawing any final conclusions. There is a ton of data the company needs to analyze and articulate. Relax.
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-324
-
- There are more pages in this discussion • 304 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $222.9M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.0¢ | $370.0K | 934.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25531 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 7985 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |